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ABSTRACT 
Background:  The injection of illicit drug and illicit drug related overdose deaths 
continues to rise across the United States.  In many parts of the country safe 
injection facilities are being considered to address the epidemic and confront 
outdoor and public injection.  To better understand injection drug users who 
injection in public or outdoor locations, we examined the demographic and 
behavior correlates associated with this practice.  Hepatitis C virus (HCV) 
infection remains a significant public health problem in the United States, with 
people who inject drugs disproportionately afflicted.  Over the last decade 
rates of heroin use have increased, with young persons (18-25 years) 
demonstrating the largest increase.  
 
Methods: We conducted a cross-sectional study in young people who currently 
injected illicit drugs (age 18-35 or ≤ 5 years of illicit drug injection) in the Lower 
East Side of New York City from 2005 to 2012 to examine the risk factors 
associated with public and outdoor injection drug use as well as antibodies to 
HCV among young adults who began injecting during the era of syringe 
services programs.  
 
Results: Among the 714 participants enrolled, 53.9% of participants injected 
predominately in public and outdoor spaces and the prevalence of antibodies 
to HCV was 48.0%.  The majority of participants identified as homeless 
(68.8%), white (74.5%), and male (68.3%).  Characteristics independently 
associated with public and outdoor injection included homelessness, 
methamphetamine use, recent incarceration, and less hygienic injection 
practices.  Risk factors independently associated with HCV seropositivity 
  
included older age, more years injection, higher injection frequency, injecting 
crack/cocaine, history of overdosed, lacking confidence in being able to avoid 
HCV infection, using more used syringes, and injecting primarily in 
public/outdoors spaces. 
 
Conclusion: Our findings indicate a substantial percentage of young injection 
drug users in the Lower East Side of New York City are injecting 
predominately in outdoor and public locations.  These findings suggest that 
currently debated harm reduction interventions such as safe injection 
facilitates may be able to impact the negative consequences of injection illicit 
drug use.  Despite access to needle exchange program in New York City, the 
seroprevalence of hepatitis C in young and recent injectors remains high.  Risk 
factors associated with more active substance use (more years injecting) are a 
strongly associated with HCV infection.  Additionally this is the first study to 
demonstrate an association between public and outdoor injection and hepatitis 
C infection.  In light of the growing acceptance of supervised injection facilities 
in many cities around the world, studying the potential impact of these facilities 
on public and outdoor injection and HCV transmission could provide added 
evidence to support their implementation.   
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CHAPTER ONE 
 
INTRODUCTION 
Injection of illicit drugs is associated with a myriad of serious threats, including 
overdose, skin and soft tissue infection, and transmission of blood-borne 
infections (including HIV, HBV, and HCV).  Despite growing public awareness 
of injection drug use, illicit injection drug use continues to increase within the 
United States with heroin use increasing 63% between 2002 and 2013, and an 
even higher increase noted in individuals aged 18-251.   In New York City, 
2014 marked the fourth consecutive year where heroin overdose deaths have 
increased2.  This increase in overdoses has occurred despite New York City’s 
extensive initiatives to distribute the overdose antidote, naloxone3.  Risk 
factors that have been associated with non-fatal overdose include binge drug 
use, requiring help injecting, homelessness, and outdoor and public injection4.  
With the goal of reducing overdose deaths by decreasing public/outdoor 
injection drug use, several advocacy groups, including The New York 
Academy of Medicine, have recently called for the establishment of supervised 
injection facilities5.   
 
Harm reduction strategies aim to mitigate the negative consequences of drug 
use.  Needle and syringe programs (NSPs) are one harm reduction 
intervention developed to decrease the transmission of blood-borne infections 
such as HIV, hepatitis B, and hepatitis C and have been instituted in 33 states, 
operating within 196 cities within the United States6.  Supervised injection 
facilities were first established over a decade ago to offer a safe and hygienic 
environment for people to inject drugs under medical supervision with the goal 
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of decreasing overdoses, injection related infections, and public injection drug 
use.  There are currently close to 100 supervised injection facilities around the 
world within 10 countries (Australia, Canada, Denmark, Germany, Greece, 
Luxembourg, the Netherlands, Norway, Spain, and Switzerland), however 
none in the United States7.  Data from these facilities has demonstrated 
reduced public injecting8, safer injecting practices of participants (e.g. less 
rushed injecting, safer needle and syringe disposal)9,10, increased access to 
drug treatment11,12, and a significant reduction in injection drug related 
overdoses in surrounding areas13,14.  Additionally modeling studies have 
suggested that these facilities could reduce the transmission of blood-borne 
pathogens, such as HIV and Hepatitis C, by decreasing the sharing of used 
needles, syringes, and other injecting equipment15,16.  However unproven 
fears of increasing crime, community drug use, or initiation of drug user have 
prevented implementation of these facilities in the United States and New York 
City specifically.  
 
In New York City, prior data suggests that roughly half of injection drug users 
have injected in public in the last month with injection in public bathrooms, 
parks, stairwells and abandoned buildings being the most common sites17.  If 
interventions to address public and outdoor injection (such as supervised 
injection facilities) are to be pursued, better understanding of the 
demographics and injection practices of potential clientele are needed to 
maximize their impact.   The current study examines the demographics and 
injection practices of young individuals who predominately inject drugs in 
public or outdoor locations in New York City.   
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METHODS 
Between 2005 and 2012 young people who inject drug were recruited, 
consented, interviewed, and screened for potential inclusion into the Swan 
Project, a prospective cohort study looking at the risk factors for the acquisition 
of new hepatitis C infection18.  The Swan study recruited young injection drug 
users from the Lower East Side of Manhattan through outreach programs, 
NSP, and word-of-mouth.  Subjects were eligible for the study if they were 
between 18 to 35 years of age or had ≤5 years of injection drug use history, 
and had injected illicit drugs in the 30 days before enrollment. 
 
At enrollment, all participants completed a standardized questionnaire and 
underwent testing for hepatitis C antibody.  The questionnaire included 
demographic information, past substance use history, and recent substance 
use practices.  Substance use history included questions related to past 
substances used, age of initiation of drug use, drugs injected, baseline HIV 
and HCV knowledge, drug treatment history, and information about with 
whom, and when the participants first drug injection took place.  Recent 
substance use practices questions included injection frequency, size of current 
injection network, frequency of sharing of needles and drug preparation 
equipment, current injection practices to prevent infection (i.e. how drugs were 
split, how used needles were cleaned before re-use, where the injection 
events took place), setting of injection drug use, and engagement in 
substance abuse treatment.  Written consent was obtained from all subjects 
and the protocol was approved by the Weill Cornell Medical College 
Institutional Review Board. The demographics and drug use patterns were 
compared for participants who primarily injected in public or outdoor locations 
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with those that primarily injected in a private residence (personal, partners, 
friends, or relatives).  Chi-squared testing was used to explore demographic 
characteristics and potential risk factors associated with public or outdoor 
injection.  Multiple logistic regression analysis was performed to determine 
which demographic and behavioral characteristics were independently 
associated with primarily injecting in public or outdoor locations.  Collinearity of 
variables was assessed prior to model development and in cases where the 
Pearson correlation coefficient was >0.5, only one of the collinear variable was 
included in the multiple logistic regression model.  A backwards stepwise 
elimination was performed with a threshold for removal of 0.10.  Adjusted odds 
ratios (AOR) and p values were calculated.  All analyses were performed 
using STATA software (v 13.1; StataCorp, College Station, TX). 
 
RESULTS 
A total of 714 active injection drug users were recruited, with 385 (53.9%) 
reporting that their primary location of injecting was a public and/or outdoor 
location.  The average age of all subjects was 24.9 years, the majority of 
whom were male (68.3%) and self-identified as white (74.5%).  Most of the 
participants were currently homeless (68.8%), unemployed (95.0%), and used 
a NSP as their primary source of needles (59.1%).  On average participants 
had been injecting drugs for 6.0 years, with a median number of daily 
injections of 2 (mean 2.9).    
 
Demographic characteristics that were associated with primarily injecting in 
public or outdoor locations included younger age, self-identifying as currently 
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homeless, being street homeless during the last 6 months, lacking a high 
school diploma, and being unemployed.    
 
The duration of an individual’s injecting career was not associated with 
public/outdoor injection, however participants who began injecting drugs at a 
younger age were more likely to be currently injecting in public or outdoors.  
Injection frequency (number of injections over the last month) was positively 
associated with public and outdoor injection.  95.9% of the studies participants 
had injected heroin within the last months, while injection of other illicit drugs 
was common with 51.3% having injected cocaine or crack during that time 
period.  A history of injecting prescription opioids and active and past injection 
of methamphetamines was more common in individuals who injected in public 
and outdoor settings.  Participants who primarily injected in outdoor or public 
spaces reported injecting with a used syringes that had been used by 
someone else more frequently, and were less likely to wash their hands prior 
to injecting. 
 
A history of overdose was reported in 57.4% of study participants, and outdoor 
and public injectors more likely to have overdosed.  Participants who injected 
in public or outdoor locations were more likely to be clients of a needle syringe 
program and conversely less likely to acquire needles from a pharmacy.  
Outdoor and public injectors were more likely to have spent the night in jail in 
the last 6 months, and more likely to have been arrested for possession of 
needles or syringes (without other charge).   
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Table 1.1 Demographic and behavioral characteristics associated with public 
and outdoor injection drug use, New York City, 2005-2012 
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Table 1.1 
 
Variable 
Overall 
(n=714) 
inject in 
public 
(n=385) 
OR 95% CI p 
Age, y <0.001 
18-19 99 (13.9) 66 (66.7) 1.00 - 
 
20-24 279 (39.1) 164 (58.8) 0.71 0.44 1.15   
25-29 207 (29.0) 102 (49.3) 0.49 0.30 0.80   
30-34 103 (14.4) 45 (43.7) 0.39 0.22 0.69 
 
≥35 [35-55] 26 (3.6) 8 (30.8) 0.22 0.09 0.56   
Gender 0.370 
Male 488 (68.3) 268 (54.9) 1.00 - 
 
Female 226 (31.7) 117 (51.8) 0.97 0.72 1.31   
Race 0.033 
White 532 (74.6) 293 (55.1) 1.00 - 
 
Black 25 (3.5) 16 (64.0) 1.45 0.63 3.34   
Latino 108 (15.2) 51 (47.2) 0.73 0.48 1.11   
Asian 7 (1.0) 2 (28.6) 0.33 0.06 1.70 
 
Mixed 31 (4.6) 13 (41.9) 0.59 0.28 1.23   
Other 10 (1.4) 9 (90.0) 7.34 0.92 58.36   
Homeless (self identified) 491 (68.8) 324 (66.0) 5.15 3.64 7.30 <0.001 
Street homeless in last 6 
months 
538 (75.4) 354 (65.8) 9.00 5.87 13.79 <0.001 
Homeless shelter in last 6 
months 
159 (22.3) 84 (52.8) 0.95 0.66 1.35 0.754 
HS diploma or GED 517 (72.4) 265 (51.3) 0.68 0.48 0.94 0.021 
Currently employed 36 (5.1) 11 (30.6) 0.36 0.17 0.74 0.004 
Exchanged sex for money 
or drugs 
202 (28.3) 112 (55.4) 1.09 0.79 1.51   
Year of injecting 0.679 
<1 year 99 (13.9) 57 (57.6) 1.00 -  
1-4 years 213 (29.8) 118 (55.4) 0.92 0.57 1.48  
5-10 years 239 (33.5) 122 (51.0) 0.77 0.48 1.23  
>10 years 163 (22.8) 88 (54.0) 0.87 0.52 1.43  
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Table 1.1 Continued 
 
Age at first injection <0.001 
<15 73 (10.2) 47 (64.4) 1.00 -  
15-17 253 (35.4) 157 (62.1) 0.91 0.53 1.56  
18-19 161 (22.6) 88 (54.7) 0.67 0.38 1.18  
20-24 155 (21.7) 69 (44.5) 0.44 0.25 0.79  
>25 72 (10.1) 24 (33.3) 0.28 0.14 0.55  
Injection frequency (injections/month) 0.022 
<30 213 (30.7) 114 (53.3) 1.00 -  
30-59 111 (15.6) 52 (46.8) 0.81 0.51 1.28  
60-89 110 (15.4) 51 (46.4) 0.80 0.50 1.26  
90-149 148 (20.7) 88 (59.5) 1.35 0.89 2.06  
150-299 96 (13.5) 64 (66.7) 1.84 1.12 3.04  
≥300 30 (4.2) 16 (53.3) 1.05 0.49 2.26  
Drugs ever injected 
 
Heroin 708 (99.2) 384 (54.2) 5.93 0.69 50.98 0.066 
Cocaine or crack 571 (80.0) 309 (54.1) 1.04 0.72 1.50 0.835 
Speedball 511 (71.6) 287 (56.2) 1.37 0.99 1.90 0.056 
Methamphetamines 285 (39.9) 193 (67.7) 2.59 1.89 3.54 <0.001 
Prescription opioids 374 (52.4) 220 (58.8) 1.52 1.13 2.04 0.006 
Ketamine 204 (28.6) 116 (56.9) 1.18 0.85 1.64 0.319 
Drug injected in last month 
 
Heroin 685 (95.9) 376 (54.9) 2.70 1.21 6.02 0.012 
Cocaine or crack 365 (51.3) 205 (56.2) 1.19 0.89 1.60 0.251 
Speedball 221 (31.0) 125 (56.6) 1.16 0.84 1.60 0.357 
Methamphetamines 28 (3.9) 21 (75.0) 2.65 1.11 6.31 0.023 
Prescription opioids 123 (17.3) 68 (55.3) 1.07 0.72 1.57 0.753 
Ketamine 27 (3.8) 14 (51.9) 0.91 0.42 1.97 0.820 
History of overdose 410 (57.4) 236 (57.6) 1.41 1.05 1.90 0.023 
NSP Client 627 (87.8) 352 (56.1) 2.10 1.32 3.32 0.001 
Spent night in jail in last 6 
months 
402 (56.3) 254 (63.2) 2.37 1.75 3.21 <0.001 
Ever arrested for 
possessing needles or 
syringes 
118 (16.5) 76 (64.4) 1.68 1.12 2.53 0.012 
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Table 1.1 Continued 
 
Clean skin with alcohol before injecting 0.063 
Never 241 (33.8) 135 (56.0) 1.00 -  
Occasionally (1-25%) 262 (36.7) 152 (58.0) 1.09 0.76 1.55  
About half the time 
(26-74%) 
76 (10.6) 35 (46.1) 0.67 0.40 1.13 
 
Most of the time (75-
99%) 
62 (8.7) 33 (53.2) 0.89 0.51 1.56 
 
Always 73 (10.2) 30 (41.1) 0.55 0.32 0.93  
Wash hands before injecting <0.001 
Never 278 (38.9) 180 (64.7) 1.00 -  
Occasionally (1-25%) 213 (29.8) 113 (53.1) 0.62 0.43 0.89  
About half the time 
(26-74%) 
97 (13.6) 45 (46.4) 0.47 0.30 0.75 
 
Most of the time (75-
99%) 
60 (8.4) 26 (43.3) 0.42 0.24 0.73 
 
Always 66 (9.2) 21 (31.8) 0.25 0.14 0.45  
Used needle or syringe used before you, last 6 months 0.017 
None 325 (45.6) 167 (51.4) 1.00 -  
1-3 times 134 (18.8) 67 (50.0) 0.95 0.63 1.42  
4-9 times 80 (11.2) 49 (61.2) 1.50 0.91 2.47  
10-25 times 69 (9.7) 49 (71.0) 2.32 1.32 4.07  
More than 25 times 105 (14.7) 53 (50.5) 0.96 0.62 1.50  
Primary source of needles or syringes <0.001 
Needle Syringe 
Program (NSP) 
422 (59.1) 249 (59.0) 1.00 - 
 
Another Person who 
got from NSP 
94 (13.2) 56 (59.6) 1.02 0.65 1.61 
 
Pharmacy without 
prescription 
177 (24.8) 72 (40.7) 0.48 0.33 0.68 
 
Pharmacy with 
prescription 
1 (0.1) 1 (100.0) - 
   
On the street 6 (0.8) 4 (66.7) 1.39 0.25 7.67  
Other 12 (1.7) 3 (25.0) 0.23 0.06 0.87  
 
On multiple logistic regression analysis, demographic and drug use 
characteristics that were independently associated with primarily injecting in 
public or outdoor locations included being currently homeless, having been 
street homeless in the last 6 months, a history of ever injecting crack or 
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cocaine, a history of ever injecting methamphetamines, having spent a night in 
jail in the last 6 months, less hand washing before injecting, and less use of 
used needles or syringes.   
 
Table 1.2 Multivariate analysis of factors associated with public and outdoor 
injection drug use, New York City, 2005-2012 
 
Variable AOR (95% CI) p 
Homeless (self-identified) 3.14 (2.09 - 4.72) <0.001 
Street homeless in last 6 months 3.73 (2.29 - 6.08) <0.001 
Year of injecting 0.95 (0.91 - 0.99) 0.014 
Age at first injection 0.93 (0.89 - 0.97) 0.002 
Drugs ever injected 
Cocaine or crack 0.56 (0.35 - 0.92) 0.020 
Methamphetamines 2.00 (1.37 - 2.94) <0.001 
Drug injected in last month 
Heroin 2.38 (0.95 - 5.96) 0.064 
Prescription opioids 0.67 (0.43 - 1.07) 0.093 
NSP Client 
Injection frequency (log transformed) 1.17 (1.01 - 1.35) 0.039 
Spent night in jail in last 6 months 1.74 (1.21 - 2.49) 0.003 
Wash hands before injecting 0.81 (0.70 - 0.93) 0.004 
Used needle or syringe used before you, last 6 months 0.87 (0.77 - 0.99) 0.036 
 
 
DISCUSSION 
Our study found that outdoor and public injection is common amongst young 
injection drug users recruited in the Lower East Side neighborhood of New 
York City.  One of the strongest associations seen with public and outdoor 
injection was unstable housing.  Not surprising current homelessness was 
strongly associated with predominant current outdoor or public injection.  
Interestingly, although current homelessness and homeless in the last six 
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months had some degree of collinearity, each was independently associated 
with public and outdoor injection on multiple logistic regression analysis. 
 
Certain illicit drugs were associated with public and outdoor injection.  
Specifically a history injecting methamphetamine was positively associated 
with outdoor and public injection, while injection cocaine use was negatively 
associated.  These unexpected findings may be a result of sampling bias, 
specifically the oversampling of a group unofficially called “urban nomads”19.  
These individuals who migrate around the United States, frequent the Lower 
East Side in the summers, and were anecdotally more likely to be homeless, 
and have a history of injection methamphetamine use.  Unfortunately the 
questionnaire used in this study was unable to clearly capture what 
percentage of our total study population identified with this lifestyle. 
 
Not surprisingly public and outdoor injection was associated with less sterile 
injection practices.  Specifically individuals who injected in public and outdoors 
were less likely to wash their hands before administering an injection.  
Interestingly the use of alcohol to clean the injection site was not statistically 
different from public versus private injection potentially demonstrating high 
uptake of harm reduction practices and utilization of NSP. 
 
One of the potential negative ramifications of public and outdoor injection is 
the increase in incarceration in this group of injection drug users.  Individuals 
who inject in public and outdoor places are often rushed through their injection 
steps for fear of getting caught and arrested9.   
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Safe injection facilities provide a means to address some of the issues raised 
in this study about outdoor and public injection.  These SIF provide a site 
where an injection drug user has access to water, clean supplies, and can 
inject without feeling rushed or looking over his shoulder.  These sites have 
been shown to decrease the density of publically discarded syringes and 
injection related litter20, while also decreasing incarceration for minor drug 
offences. 
 
This study has several limitations.  The ability to generalize this study to all 
injection drug users is limited by the fact that recruitment for the study 
occurred in close association with a single NSP.  Although we used multiple 
forms of recruitment to attract participants not currently seeking services at the 
NSP, the majority of participants still obtained their injection equipment from a 
SNP and the substance use practices of these individuals likely differs from 
the injecting drug using population as a whole.  Additionally the geographic 
area of the Lower East Side of New York City where the study occurred and 
the most participants were recruited from is likely ethnically, socio-
economically different from other neighborhoods with significant injection drug 
using populations.  Historically the Lower East Side SNP has attracted a 
younger and whiter client population compared to other SNP in Manhattan or 
other Boroughs.     
 
An additional limitation of the study was the cross sectional design of this 
study, which relied heavily on self-report demographic and behavioral 
patterns.  The study design employed in this project creates the potential for 
recall bias, especially when attempting to remember several years in the past.  
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Additionally, several questions addressed sensitive topics related to drug use 
and sexual practices.  These types of questions (related to drug use or sexual 
practices) are often associated with societal stigmas, and participants may not 
be entirely forthcoming or comfortable admitting to a known stigmatized 
behavior. Finally, despite there being several significant associations noted 
between demographics or behavior and outdoor and public injection, 
concluding a causative implication of these is not possible in a cross-sectional 
design.  
 
Heroin use and heroin related overdose death have increased dramatically in 
the United States over the last decade.  Evidence from Canada and Europe 
have clearly demonstrated that novel harm reductive interventions such as 
supervised injection facilities can significantly reduce many negative 
consequences of injection drug use including overdose deaths, especially in 
marginalized individuals who previously injected in public places.  The time 
has come for State and local governments to overcome strongly held societal 
stigmas surrounding injection drug use, and to aggressively address the 
epidemic through implementation of evidence-based harm reduction 
intervention.   
15 
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CHAPTER TWO 
 
INTRODUCTION 
Hepatitis C virus (HCV) is the most common blood-borne pathogen in the 
United States, with chronic infection being a leading cause of cirrhosis and 
liver cancer1, with death associated with HCV infection surpassing all other 60 
notifiable infectious diseases combined2. Although hepatitis C incidence 
estimates in the general population declined from 1992 to 20093, between 
2009 and 2013 rates of acute infection have more than doubled4 with rates in 
people who inject drugs (PWID) remain alarmingly high.  Efficiently transmitted 
via contaminated needles and syringes, HCV is endemic in PWID.   
 
Injection drug users who share needles, syringes, or other injection equipment 
are at the highest risk for contracting HCV 1,5.  The prevalence of HCV 
infection in injection drug using populations varies widely around the world 
with an estimated 70-90% of IDUs in the US are infected with HCV6–11, 
although the prevalence among those who have been injecting < 5 years has 
fallen considerably since the implementation of education, outreach, and clean 
needle programs7,9,12–16.  Needle and syringe programs were developed to 
reduce the transmission of blood-borne infections such as HIV, hepatitis B, 
and hepatitis C and have been instituted in 33 states, operating within 196 
cities within the United States17.  Data suggests that needle syringe programs 
have made a significant impact on the incidence and prevalence of HCV 
transmission and infection in PWID5,18,19, although both remain alarmingly high 
in the United States20–22.    
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The United States is experiencing a dramatic opioid epidemic over the last 
several years, especially affecting young people, and has spurred an alarming 
increase in HCV transmission as opioid-dependent people turn to injection.  
This has widely affected communities with little or no access to HIV prevention 
interventions resulting in rapid spread of HCV23, and even putting them at risk 
for HIV transmission, such as demonstrated recently in Indiana24.  Between 
2002 and 2013 heroin use in the United States has increased by 63%, with the 
highest increase in young persons age 18-2525.  This rise in heroin use in 
young people has been accompanied by increases in HCV infection in young 
PWID26–30.   
 
Despite the impact of HIV prevention interventions, and increased availability 
of sterile injection equipment on reducing the incidence of HCV over the last 
20 years, transmission remains alarmingly high and is now rising with a new 
wave of HCV transmission occurring on the heels of the injection opioid 
epidemic.  Certain demographic characteristics and risk behaviors have 
consistently been associated with HCV infection.  These risk factors include 
older age, more years injecting drugs, greater frequency of injection drug use, 
and injection of cocaine21,31–34.   However more information is needed about 
why HCV continues to spread among people who use drugs where they do 
have access to existing interventions.  This information will be particularly 
important as efforts are made to arrest the spread of HCV among the many 
communities newly affected by the opioid epidemic.  
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This study examines data from the Swan Project to explore mechanisms of 
HCV spread and potentially modifiable risk factors for transmission in a group 
of young active injection drug users in New York City.  
 
METHODS 
Between 2005 and 2012, the Swan Project recruited young people who inject 
drugs (PWID) on the Lower East Side of Manhattan through outreach, 
community-based agencies, and word-of-mouth. Eligible participants were 
between 18 to 35 years of age or had injected drugs for ≤5 years, and had 
injected illicit drugs in the 30 days before enrollment. Participants were 
interviewed, tested for hepatitis C, and screened for a prospective cohort study 
on the acquisition of new hepatitis C infection 35.     This study reports baseline 
data on all eligible participants with HCV antibody data available. 
 
At enrollment, all participants underwent a face-to-face interview using a 
standardized questionnaire and were tested for hepatitis C antibody.  The 
questionnaire included questions about demographic characteristics past and 
current substance use and other experiences.  Questions about past 
substance use queried substances used, age of initiation of drug use, drugs 
injected, baseline HIV and HCV knowledge, and information about with whom, 
when, and where the participant’s first drug injection took place.  Questions 
about recent substance use addressed injection frequency, injection network, 
frequency of sharing of needles and drug preparation equipment, current 
injection practices to prevent infection (i.e. how drugs were split, how used 
needles were cleaned before re-use), setting of injection drug use, and 
engagement in treatment for substance use.  Blood was collected from each 
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participant and tested for HCV antibodies by second (HCV EIA 2.0, Abbott 
Laboratories, Abbott Park, IL) or third (HCV 3.0 ELISA and RIBA HCV 3.0, 
Ortho Clinical Diagnostics, Raritan, NJ) generation tests.  Written consent was 
obtained from all subjects and the protocol was approved by the Institutional 
Review Boards of Weill Cornell Medical College, Beth Israel Medical Center, 
and SUNY Downstate College of Medicine. 
 
The demographics and drug use patterns were compared for participants who 
were HCV antibody positive and HCV antibody negative.  Chi-square testing 
was used to explore risk factors associated with HCV antibody (Ab) positivity.  
Logistic regression models were used to calculate odds ratios (OR) and 
confidence intervals.  Multiple logistic regression analysis was performed to 
determine which demographic and behavioral characteristics were associated 
with HCV seropositivity independently of specific injection practices postulated 
to result in HCV transmission.  Collinearity of variables was assessed prior to 
model development and in cases where the Pearson correlation coefficient 
was >0.5, only one of the collinear variable was included in the multiple logistic 
regression model.  Continuous variables with skewed distribution were log 
transformed prior to analysis (e.g., injections per month). This improved the fit 
of the multivariate models.  A hierarchical multiple logistic model was created 
where factors hypothesized to represent potential mechanisms of transmission 
were first assessed, and then controlled for when subsequent social, 
behavioral and contextual factors were added to the model.  Adjusted odds 
ratios (AOR) and p values were calculated.  All analyses were performed 
using STATA software (v 13.1; StataCorp, College Station, TX). 
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RESULTS 
The Swan Project recruited 714 eligible participants who met the eligibility 
criteria.  Their median age was 24 years (mean 24.9).  Three-quarters of the 
participants identified as white, and nearly three-quarters had a high school 
education or the equivalent (Table 2.1). Two-thirds reported being homeless. 
The median duration of injecting drugs was 5 years (mean 6.0 years).  The 
median number of injections during the prior 30 days was 60 (mean 87.8).   
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Table 2.1 HCV seroprevalence by demographics characteristics, 
young people who inject drugs, New York City 2005-2012
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Table 2.1  
 Variable Overall HCV Ab (+) OR 95% CI p 
TOTAL 714 (100%) 343 (48.0%)         
Age, y  <0.001* 
18-19 99 (13.9%) 21 (21.2%) 1.00 REF 
 20-24 279 (39.1%) 116 (41.6%) 2.64 1.54 4.52   
25-29 207 (29.0%) 125 (60.4%) 5.66 3.24 9.88   
30-34 103 (14.4%) 66 (64.1%) 6.63 3.54 12.41   
≥35 [35-55] 26 (3.6%) 15 (57.7%) 5.06 2.03 12.65   
Gender  0.209 
Male 486 (68.1%) 241 (49.6%) 1.00 REF 
 Female 222 (31.1%) 99 (44.6%) 0.82 0.59 1.13   
Ethnicity   0.137 
White 532 (74.6%) 265 (49.8%) 1.00 REF 
 Black 25 (3.5%) 7 (28.0%) 0.39 0.16 0.95   
Latino 108 (15.2%) 108 (48.2%) 0.94 0.62 1.42   
Asian 7 (1.0%) 1 (14.3%) 0.17 0.02 1.4   
Mixed 31 (4.4%) 13 (41.9%) 0.73 0.35 1.52   
Other 10 (1.4%) 5 (50.0%) 1.01 0.29 3.52   
Currently homeless   0.006 
No 223 (31.2%) 90 (40.3%) 1.00 REF 
 Yes 491 (68.8%) 253 (51.5%) 1.57 1.14 2.17   
High School Diploma or GED  0.148 
No 197 (29.6%) 86 (43.7%) 1.00 REF 
 Yes 517 (72.4%) 257 (49.7%) 1.28 0.92 1.77   
Currently employed   0.031 
No  677 (95.0%) 332 (49.0%) 1.00 REF 
 Yes 36 (5.0%) 11 (30.6%) 0.46 0.22 0.94   
* Mantel-Haenszel chi-square test for tren 
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Of the 714 participants, 343 (48.0%) had a positive HCV antibody test at 
enrollment, indicating either past or present HCV infection (Table 2.1). Of the 
466 participants in the study who reported being tested previously for hepatitis 
C, only 180 reported a prior positive test. Thus, 47.5% of those found with 
positive HCV antibody during our study were new diagnoses.  Several 
demographic characteristics were associated with HCV seropositivity (Table 
2.1).    The risk of being HCV antibody-positive increased markedly with 
increasing age (Table 2.1).  Although most of the people in the study were 
men, gender did not impact the likelihood of being infected with HCV.  Social 
factors that were significantly associated with being infected with HCV 
included being homeless and being unemployed. 
 
Study Participants had been injecting drugs for a median of 5 years (mean 
6.0) and those who had injected longer were at dramatically increased risk for 
having HCV antibodies (Table 2.2). Of participants who had injected for 10 
years or more, 68.1% had HCV antibodies. Most (80.4%) participants had 
been given their first injection by another person. The older the age of that 
person, the more likely the participant was to have been infected.  Only 67.5% 
of participants knew that hepatitis C could be transmitted by sharing needles 
when they began injecting, and those that lacked this understanding were at 
increased risk for becoming infected.  In contrast, 92.0% of subjects were 
aware of HIV transmission through contaminated needles, and this 
understanding was not a significant risk or protective factor for HCV 
acquisition. Participants were at least somewhat aware of the magnitude of 
their own risk. Excluding those who reported a prior positive HCV test, 
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participants’ lack of confidence in their ability to avoid infection was associated 
with a positive HCV antibody test.  
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Table 2.2 HCV seroprevalence by injection drug use characteristics, young 
people who inject drugs, New York City 2005-2012 
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Table 2.2 
Variable Overall HCV Ab (+) OR 95% CI p 
TOTAL 714 (100%) 343 (48.0%)         
Duration of injection drug use <0.001* 
<1 99 (13.9%) 20 (20.2%) 1.00 REF   
1-4 213 (29.8%) 72 (33.8%) 2.02 1.14 3.56   
5-9 239 (33.5%) 140 (58.6%) 5.59 3.21 9.72   
≥10 163 (22.8%) 111 (68.1%) 8.43 4.67 15.22   
Who administered first injection 0.58 
Self 140 (19.6%) 65 (46.4%) 1.00 REF 
 
         Primary sex partner 96 (13.4%) 48 (50.0%) 1.15 0.69 1.94   
Other sex partner 14 (2.0) 7 (50.0%) 1.15 0.38 3.46   
A relative or close friend 327 (45.8%) 150 (43.7%) 0.98 0.66 1.45   
Dealer, gallery operator, 
hit doctor 
15 (2.1%) 8 (53.3%) 1.32 0.45 3.83   
Acquaintance 116 (16.2%) 60 (51.7%) 1.24 0.76 2.02   
Other 6 (0.8%) 5 (83.3%) 5.77 0.66 50.66   
Age of person who administered your first injection  0.039*† 
Self 140 (19.6%) 65 (46.4%) - - 
 
<20 194 (27.2%) 87 (44.9%) 1.00 REF 
 
20-24 174 (24.4%) 78 (44.8%) 1.00 0.66 1.51   
25-29 101 (14.1%) 50 (49.5%) 1.21 0.74 1.95   
≥30 96 (13.4%) 58 (60.4%) 1.88 1.14 3.09   
Before first injection knew HIV could be transmitted by sharing needles 0.2 
No 57 (8.0%) 32 (56.1%) 1.00 REF 
 
Yes 657 (92.0%) 311 (47.3%) 0.70 0.41 1.21   
  
Before first injection knew hepatitis could be transmitted by sharing needles <0.001 
No 232 (32.5%) 140 (60.3%) 1.00 REF 
 
Yes 482 (67.5%) 203 (42.1%) 0.48 0.35 0.66   
Before first injection knew hepatitis could be transmitted by sharing cottons, cookers, 
or rinse water 
0.1 
No 458 (64.3%) 230 (50.2%) 1.00 REF 
 
Yes 254 (35.7%) 111 (43.7%) 0.77 0.57 1.05   
Confident in avoiding getting hepatitis C virus  <0.001‡ 
Extremely confident 180 (32.4%) 45 (25.0%) 1.00 REF 
 
Somewhat confident 230 (41.4%) 70 (30.4%) 1.31 0.85 2.04   
A little confident 72 (13.0%) 29 (40.3%) 2.02 1.13 3.61   
Not confident at all 74 (13.3%) 49 (66.2%) 5.88 3.27 10.59   
Self-reported HCV-positive 180  165 (91.7%) - - -  
*Mantel-Haenszel chi-square test for trend;   †Excludes those who self-injected;  ‡Excluded self-reported 
positive 
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Heroin was injected by 99.2% of our participants, and many injected other 
substances as well (Table 2.3). Injection of several of these additional illicit 
agents (cocaine, prescription pain killers, crystal meth, and ketamine) was 
associated with being at increased risk for hepatitis C infection.   57.4% of our 
participants reported having overdosed in the past, and these individuals were 
more likely to have a positive HCV antibody test than those who had never 
overdosed.  Additional risk factors associated with HCV seropositivity included 
having exchanged sex for money or drugs and having been arrested solely for 
drug residue or possession of needle or syringe. 
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Table 2.3 HCV seroprevalence by injection and other experiences, young 
people who inject drugs, New York City, 2005-2015 
 Variable Overall HCV Ab (+) OR 95% CI p 
TOTAL 714 (100%) 343 (48.0%)    
Ever injected heroin 0.5 
No  6 (0.8%) 2 (33.3%) 1.00 -   
Yes 708 (99.2%) 341 (48.2%) 1.85 0.34 10.21   
Ever injected crack/cocaine <0.001 
No  143 (20.0%) 34 (23.8%) 1.00 -   
Yes 571 (80.0%) 309 (54.1%) 3.78 2.49 5.75   
Ever injected pharmaceutical pain killers 0.009 
No 616 (86.3%) 284 (46.1%) 1.00 -   
Yes 98 (13.7%) 59 (60.2%) 1.77 1.15 2.73   
Ever injected crystal meth 0.001 
No  429 (60.1%) 185 (43.1%) 1.00 -   
Yes 285 (39.9%) 158 (55.4%) 1.64 1.21 2.22   
Ever injected ketamine 0.047 
No 510 (71.4%) 233 (45.7%) 1.00 -   
Yes 204 (28.6%) 110 (53.9%) 1.39 1 1.93   
Ever overdosed <0.001 
No 304 (42.6%) 104 (34.2%) 1.00 -   
Yes 410 (57.4%) 239 (58.3%) 2.69 1.98 3.66   
Ever been given money or drugs in exchange for sex? 0.02 
No 512 (71.7%) 232 (45.3%) 1.00 -   
Yes 202 (28.3%) 111 (55.0%) 1.47 1.06 2.04   
Ever arrested solely for drug residue or possession of syringe or needle <0.001 
No 579 (81.1%) 239 (41.3%) 1.00 -   
Yes 135 (18.9%) 104 (77.0%) 4.77 3.09 7.36 
  
 
Recent injection practices that were associated with increased HCV antibody 
positivity included higher injection frequency, more frequent use of syringes 
previously used by another person, use of syringes previously used by more 
people, and less frequent cleaning of skin with alcohol (Table 2.4).  53.9% of 
our study participants most frequently injected most often in public or outdoor 
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locations, and this practice was associated with HCV antibody positivity.  
Splitting drug within a cooker in the last 6 months was not associated with 
HCV seroposivity, while splitting drug with a used syringe was. 
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Table 2.4 HCV seroprevalence by recent injection practices, young people 
who inject drugs, New York City, 2005-2012 
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Table 2.4 
Variable Overall HCV Ab (+) OR 95% CI p 
TOTAL 714 (100%) 
343 
(48.0%)         
Injection frequency (injections/month) <0.001 
<30 219 (30.7%) 86 (39.3%) 1.00 - 
 
30-59 111 (15.6%) 43 (38.7%) 0.98 0.61 1.56   
60-89 110 (15.4%) 56 (50.9%) 1.60 1.01 2.55   
90-149 148 (20.7%) 85 (57.4%) 2.09 1.37 3.19   
150-299 96 (13.5%) 52 (54.2%) 1.83 1.13 2.97   
≥300 30 (4.2%) 21 (70.0%) 3.61 1.58 8.28   
Location where injected drugs most (last 6 months) 0.008 
Your or primary partner's home 187 (26.2%) 72 (38.5%) 1.00     
 
Home of a friend or relative 79 (11.1%) 32 (40.5%) 1.09 0.64 1.86 
 
Public or outdoor space 358 (53.9%) 
206 
(53.5%) 1.84 1.29 2.62 
 
Other indoor space 37 (5.2%) 19 (51.4%) 1.68 0.83 3.42 
 
Other 26 (3.6%) 14 (53.9%) 1.86 0.82 4.25 
 
No. times splitting drug solution with a previously used syringe (past 6 months) <0.001 
Never 325 (45.6%) 
131 
(40.3%) 1.00 - 
 
1-3 times 134 (18.8%) 59 (44.0%) 1.16 0.78 1.75   
4-9 times 80 (11.2%) 41 (51.3%) 1.56 0.95 2.54   
10-25 times 69 (9.7%) 47 (68.1%) 3.16 1.82 5.5   
>25 times 105 (14.7%) 65 (61.9%) 2.41 1.53 3.78   
No. people who used a syringe before participant (past 6 months) <0.001 
None 333 (48.2%) 
136 
(40.8%) 1.00 - 
 
1 person 168 (24.3%) 85 (50.6%) 1.48 1.02 2.15   
2 people 59 (8.5%) 26 (44.1%) 1.14 0.65 1.99   
3 people 43 (6.2%) 28 (65.1%) 2.70 1.39 5.25   
4-9 people 65 (9.4%) 41 (63.1%) 2.47 1.43 4.29   
10-25 people 18 (2.6%) 14 (77.8%) 5.07 1.63 15.73   
>25 people 5 (0.7%) 4 (80.0%) 5.79 0.64 52.41   
No. times drawing drugs from cooker used previously by someone else (last 6 months)  <0.001 
Never 317 (45.4%) 
144 
(45.4%) 1.00 - 
 
1-3 times 90 (12.9%) 28 (31.1%) 0.54 0.33 0.89 
 
4-9 times 53 (7.6%) 24 (45.3%) 0.99 0.55 1.78 
 
10-25 times 65 (9.3%) 32 (49.2%) 1.16 0.68 1.99 
 
>25 times 174 (24.9%) 
105 
(60.3%) 1.83 1.26 2.66 
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Table 2.4 Continued 
No. times drawing drugs from cotton previously accessed by someone else (past 6 
months) 0.001 
Never 323 (45.2%) 139 (43.0%) 1.00 - 
 
1-3 times 107 (15.0%) 42 (39.3%) 0.86 0.55 1.34 
 
4-9 times 81 (11.3%) 43 (53.1%) 1.50 0.92 2.44 
 
10-25 times 77 (10.8%) 40 (52.0%) 1.43 0.87 2.36 
 
>25 times 126 (62.7%) 79 (62.7%) 2.23 1.46 3.40 
 
No. times using rinse water previously accessed by someone else (past 6 months) 0.022 
Never 346 (48.5%) 154 (44.5%0 1.00 - 
 
1-3 times 109 (15.3%) 46 (42.2%) 0.91 0.59 1.41 
 
4-9 times 68 (9.5%) 32 (47.1%) 1.11 0.66 1.87 
 
10-25 times 57 (8.0%) 31 (54.4%) 1.49 0.85 2.61 
 
>25 times 134 (18.8%) 80 (59.7%) 1.84 1.23 2.77 
 
Frequency of cleaning skin with alcohol before injecting (last 6 months) <0.001 
never 241 (33.8%) 134 (55.6%) 1.00 - 
 
occasionally (1-25%) 262 (36.7%) 134 (51.1%) 0.84 0.59 1.19   
about half the time (26-74%) 76 (10.6%) 27 (35.5%) 0.44 0.26 0.75   
most of the time (75-99%) 62 (8.7%) 28 (45.2%) 0.66 0.38 1.15   
always 73 (10.2%) 20 (27.4%) 0.30 0.17 0.53   
Frequency of cleaning your skin with soap and water before injecting (past 6 months) 0.161 
never 437 (61.2%) 220 (50.3%) 1.00 - 
 
occasionally (1-25%) 172 (24.1%) 81 (47.1%) 0.88 0.62 1.15   
about half the time (26-74%) 42 (5.9%) 14 (33.3%) 0.49 0.25 0.96   
most of the time (75-99%) 34 (4.8%) 13 (38.2%) 0.61 0.3 1.25   
always 29 (4.1) 15 (51.7%) 1.06 0.5 2.24   
Frequency of cleaning your hands with soap and water before injecting (last 6 months) 0.017 
never 278 (38.9%) 141 (50.7%) 1.00 - 
 
occasionally (1-25%) 213 (29.8%) 109 (31.8%) 1.02 0.71 1.46   
about half the time (26-74%) 97 (13.6%) 47 (48.5%) 0.91 0.58 1.45   
most of the time (75-99%) 60 (8.4%) 19 (31.7%) 0.45 0.25 0.81   
always 66 (9.2%) 27 (40.9%) 0.67 0.39 1.16   
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Analysis of variables that potentially were mechanisms of HCV transmission 
resulted in a hierarchical model with five control variables; age, years injecting 
drugs, splitting of drug solution with a previously used syringe, drawing drugs 
from cooker used previously by someone else, and using a used syringe from 
a large number of people (Table 2.5).  In multiple regression modeling, when 
adjusting for the control variables, social and behavioral characteristics that 
remained significantly associated with HCV seroprevalence included having 
been arrested for drug residue or paraphernalia, lacking confidence in being 
able to avoid HCV infection, and injecting primarily in public/outdoors spaces 
(Table 2.5).  
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Table 2.5 Factors associated with HCV antibody in multivariate analysis*
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Table 2.5 
 
  
Variable* AOR (95% CI) p 
Control variables  
Age † 2.50 (1.72-3.62) <0.001 
Years injecting drugs † 1.65 (1.29-2.10) <0.001 
No. times splitting drug solution with a previously used syringe (past 6 
months) 1.34 (1.11-1.63) 0.003 
No. times drawing drugs from cooker used previously by someone else 
(last 6 months) † 1.14 (0.99-1.31) 0.063 
No. people who used a syringe before participant (past 6 months) 1.25 (1.05-1.50) 0.013 
Demographic variables 
Gender (male) 1.21 (0.76-1.94) 0.425 
High School Diploma or GED 1.10 (0.63-1.92) 0.739 
Currently employed 0.70 (0.22-2.22) 0.541 
Currently homeless 1.31 (0.73-2.33) 0.363 
Variables related to first illicit drug injection 
Administered own first injection  0.88 (0.45-1.72) 0.699 
Age of person who administered first injection † ‡ 1.96 (0.66-5.84) 0.225 
Before first injection knew HIV could be transmitted by sharing needles 1.02 (0.38-2.72) 0.970 
Before first injection knew hepatitis could be transmitted by sharing 
needles 0.98 (0.57-1.68) 0.940 
Before first injection knew hepatitis could be transmitted by sharing 
cottons, cookers, or rinse water 0.96 (0.57-1.63) 0.878 
Variables associated with past injection practices 
Ever injected crack/cocaine 1.67 (0.84-3.33) 0.144 
Ever injected pharmaceutical pain killers 1.08 (0.55-2.12) 0.812 
Ever injected crystal meth 0.99 (0.60-1.66) 0.984 
Ever injected ketamine 1.57 (0.90-2.72) 0.113 
Ever overdosed 1.81 (1.09-3.00) 0.210 
Ever arrested solely for drug residue or possession of syringe or needle 3.62 (1.83-7.15) <0.001 
Ever been given money or drugs in exchange for sex? 0.99 (0.58-1.70) 0.978 
Variables associated with current injection practices 
Injection frequency (past 6 months) † 1.09 (0.87-1.35) 0.455 
Injected most commonly in public/outdoors (past 6 months) 2.42 (1.44-4.06) 0.001 
Frequency of cleaning skin with alcohol before injecting (last 6 months) 0.75 (0.60-0.95) 0.015 
Frequency of cleaning your skin with soap and water before injecting 
(past 6 months) 0.90 (0.69-1.17) 0.436 
Frequency of cleaning your hands with soap and water before injecting 
(past 6 months) 0.77 (0.62-0.97) 0.026 
No. times injecting drugs using a previously used syringe (past 6 
months) 1.12 (0.90-1.40) 0.323 
No. times drawing drugs from cotton previously accesssed by someone 
else (past 6 months) 1.05 (0.87-1.26) 0.625 
No. times using rinse water previously accessed by someone else (past 
6 months) 1.01 (0.84-1.21) 0.928 
Perceived risk variables 
Self-reported HCV-positive 22.88 (8.46-61.92) <0.001 
Confident that you can avoid getting hepatitis C virus? (4-point Likert 
scale) § 1.79 (1.30-2.48) <0.001 
*All values are adjusted for the first 5 variables in the table (Control variables) 
 † log-transformed 
  ‡ Adjusted for individuals who 'Administered own first injection’ 
  § Adjusted for self-reported positive 
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DISCUSSION 
We found a high seroprevalence of HCV in in young active injection drug 
users of 48%.  The observed seroprevalence is not substantially different from 
the estimated 51% seroprevalence in New York City injection drug users of all 
ages36.  These numbers may suggests that although increasing age is a risk 
for HCV seropositivity, much of the acquisition of infection is occurring within 
the first few years of an individual commencing injecting drugs which has been 
seen in prior studies37.  Specifically, we found a disconcerting seroprevalence 
of HCV infection in individuals who have injected drugs for less than one year 
(20.2%).  This rate appears higher than the prevalence rates found in similar 
cohorts in other cities around the United States 33,36. These new injection drug 
users are seldom linked to harm reduction services and needle syringe 
exchanges programs at the time they initiate their injection career.  This, 
coupled with the fact that only two-thirds of patients in our study were aware 
that hepatitis could be transmitted through sharing of needles and syringes, 
highlights the need for HCV prevention strategies specifically identifying and 
targeting youth before they initiate injecting drugs.  Additionally, these early 
infections are important to consider when discussing the potential for HCV 
eradication.  These new injection drug users likely have poor linkage to harm 
reduction services and limited understanding of HCV transmission and 
prevention. As a result they will be one of the most difficult groups of people to 
engage in treatment, and thus represent a potential persistent reservoir of 
infection and transmission. 
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Several demographic characteristics and risk behaviors that were significantly 
associated with HCV seropositivity were consistent with prior published 
studies in injection drug using populations.  These included older age and 
more years injecting drugs.  Interestingly, injection frequency was not 
independently associated with HCV seropositivity deviating from many prior 
studies.  Instead, we were able to identify more specific sharing behaviors and 
practices within the injection pathway that, when occurring at higher 
frequency, were independent risk factors for HCV infection.  An associations 
with HCV infection was seen with the number of people who used a syringe 
before participant and the number of times drawing drug from a used cooker.  
Additionally, a never reported variable of times splitting drug solution with a 
previously used syringe was independently associated with HCV infection, 
were as number of times injecting drugs using a previously used syringe was 
not independently associated on multiple logistic models. 
 
Although HIV remains a major issue for PWID, the seroprevalence of HIV in 
this population remains significantly less than the seroprevalence of HCV.  612 
of our 714 participants reported having prior HIV testing, with only 6 individuals 
self-reporting being infected; in comparison only 466 participants had 
previously been tested for HCV.  These data suggest that the message about 
HIV transmission through drug use is permeating, while the message 
surrounding HCV transmission within this same population is lagging.  
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However, two recent developments may provide the impetus to address and 
re-prioritize HCV services in the near future.  First, within the last few years the 
nationwide age-adjusted mortality from HCV, both hepatic and extra-hepatic, 
rose above HIV for the first time38.  Second, the advent of new direct acting 
antiviral agents may provide a new opportunity to cure active injection drug 
users of their infection, with the added potential to substantially decrease 
transmission, and subsequently decrease prevalence of HCV in PWID through 
a treatment as prevention model39–41.  The high prevalence of HCV infection, 
high relative mortality associated with HCV infection, and recent advances in 
HCV treatment provide the basis for advocates and policy makers to argue 
that public health investment is needed to address issues of HCV prevention 
and treatment.   
 
What remains a challenge in the prevention of blood-borne pathogen 
transmission in PWID is ensuring a consistent supply of clean injection 
equipment.  Over half of our study participants reported the use of used 
syringes over the last six months.  More encouraging is that most of our 
participants kept a small injection network, with 82% of participants sharing 
used needles with two or fewer individuals.  If each member of a small network 
can be aviremic either through prevention or cure of their HCV, further 
transmission from or within this nidus can be terminated42.   
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Over half of our study participants injected most frequently in public or outdoor 
locations, with this factor being independently associated with HCV antibody 
positivity.  To our knowledge this is the first study to demonstrate the finding 
that public and outdoor injection is associated with HCV antibody positivity, 
although some prior studies have demonstrated the association of shooting 
galleries use and HCV acquisition43,44.  Public and outdoor injection drug use 
is often more rushed than home-based injection due to the potential/fear of 
getting caught, and the rushed nature of this practice may make the 
implementation of safe injection practices more difficult.  Over the last several 
years there has been growing support for supervised injection facilities.  
Studies have demonstrated that these facilities significantly reduce overdose 
associated mortality in the area surrounding the site45,46.  Our study, showing 
the association between public/outdoor injection and HCV, suggests that 
moving PWID indoors into supervised injection facilities may have the added 
benefit of reducing HCV transmission.  Further studies looking at this 
association may provide additional motivation to institute supervised injection 
facilities in regions with high outdoor/public injection drug use.   
 
This study has several limitations.  First, the ability to generalize this study to 
all injection drug users is limited by the fact that recruitment for the study 
occurred in close association with a needle syringe program.  Although we 
used multiple forms of recruitment to attract participants not currently seeking 
services at the needle syringe program, the potential oversampling of PWID 
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who are more engaged in harm reduction services is a potential source of 
bias.  Whether the injection practices of drug users seeking out harm reduction 
services is significantly different from those not engaged with these services 
was not captured in this study. 
 
Second, the cross sectional design of this study relied on self-report of 
potential exposures or risk behaviors.  This study design could have led to 
recall bias, especially where participants were asked about events which may 
have occurred 5 or even 10 years prior.  Additionally it is possible that 
participants were not entirely forthcoming about their risk behavior especially 
in situations where a societal stigma is associated with the behavior, such as 
sharing of syringes and needles and exchange of sex for money or drugs.  
Additionally, despite there being several significant associations noted 
between demographics or behavior and HCV seropositivity, concluding a 
causal effect is not possible.  
 
Third, this study took place in New York City where for over two decades there 
have existed independent, community-based, needle syringe programs.  As a 
result it is difficult to extend these findings to many areas of the country, 
especially non-urban settings, where injection drug use is becoming an 
increasing issue and access to clean injection equipment and harm reductive 
services is limited.   
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In this study, we noted relatively high rates of HCV infection in young active 
injection drug users, with a significant proportion being infected within one 
year of their first injection.  These early seroconversions highlight the need to 
re-evaluate the current harm reduction model when attempting to impact the 
transmission of HCV in the injection drug using populations.  There remains a 
need to identify high risk individuals before they initiate injecting drugs, and 
convey to them harm reduction messages with the goal of impacting future 
injection practices and potentially HCV incidence.  Finally, our study suggests 
a possible role for supervised injection facilities to reduce public and outdoor 
injection and subsequently decrease the transmission of HCV. 
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